HemoShear LLC's October announcement that a new
application of its in vitro tissue modeling platform to tumors reproduces the human response to cisplatin means the company
could soon tap into business from drug developers working in oncology-an area
the biotech had not yet broached.
its launch in 2008, HemoShear has been engaging with client
companies as well as partners from academia and the public sector to develop in vitro models of human tissue and organ systems to support drug discovery and understand disease
biology. Its in vitro models include 3D culture systems and incorporate
elements of in vivo physiology such as hemodynamic forces, multilayer biological transport processes and cell-to-cell
Sanofi's new CEO will have a hard row to hoe to offset Lantus declines, as the board has taken easy solutions off the table.
Lantus rebates could spell reimbursement pressure for new insulin products Sanofi and others will be launching in 2015 and 2016.
Abcodia's massive longitudinal biobank could help drug developers pinpoint how markers change at the very start of disease.
Viamet spinout Innocrin is developing VT-464 for CRPC patients resistant to Xtandi or Zytiga.
Zephyrus is developing its scWestern technology to perform Western blots on thousands of cells at once with single-cell resolution.
ODAC thinks Novartis should study different combinations or doses of panobinostat to reduce side effects in multiple myeloma.
Tox data, mechanistic insight pay off for Ziarco. Plus: Impatient's targeted donation strategy; Definiens' M&A exit.
Rep. Fred Upton (R-Mich.) said he plans to release a discussion draft in mid-January 2015 of legislation based on the 21st Century Cures initiative he and Rep. Diana DeGette (D-Colo.) launched in May.Speaking at a conference...
OncoTherapy Science has a potent TOPK inhibitor in a liposomal formulation that avoids the toxicity of other cytokinesis-targeted compounds.
Karolinska's new deputy vice chancellor, Alexander von Gabain, has plans to break down silos and breed new mindsets to maximize the institute’s translational potential.
A paper-based diagnostic using RNA switches could provide an easily distributed, rapid test for infectious diseases in point-of-care settings.
HemoShear's in vitro tumor model shows a new application for its tissue modeling technology and could open it to business from oncology companies.
Overcoming oncogenic KRAS-driven chemotherapy resistance by blocking NRF2 signaling; trifunctional arylpiperazine analogs as antipsychotic agents; inhibiting TRPM2 or RAC1 to treat ischemic kidney injury; and more...
Lysyl oxidase to enhance tensile properties of musculoskeletal grafts; a sorbitol-based PET imaging agent to help diagnose and monitor Enterobacteriaceae infections; genetic variants near estrogen receptor-alpha to predict the risk of breast cancer in Latina women; and more...